Fabentech Secures $20 Million in Funding to Advance Revolutionary Immunotherapy Solutions for Global Health Emergencies

Fabentech, a pioneering biopharmaceutical SME based in Lyon, France, has successfully raised €20 million in funding to further its mission of developing innovative immunotherapies aimed at addressing critical public health emergencies.

Established in 2009, Fabentech has positioned itself at the forefront of biodefense and infectious disease treatment through its robust F(ab')2 platform, a technology originally licensed from Sanofi Pasteur.

In a world increasingly vulnerable to epidemics and bioterrorist threats, the need for effective therapeutic options has never been more urgent.

Currently, Fabentech is advancing three key products: a biodefense antidote created in partnership with the French army, a confidential treatment for drug intoxication, and a groundbreaking Ebola therapy.

The company initially garnered attention with its Fabenflu® product, which targets avian influenza (H5N1) in humans—a testament to its commitment to combating neglected indications lacking viable treatments.

The recent funding round will not only accelerate the development of these pioneering therapies but also enhance the company's capabilities in research and clinical trials, positioning Fabentech as a key player in global health security.

With the backing of this investment, the company aims to fulfill a significant gap in public health preparedness, ensuring that nations are equipped to handle medical emergencies effectively.

Fabentech's advancements could potentially save lives and shape the future of biopharmaceutical interventions in times of crisis, solidifying its role as a leader in the industry.